Valuation: EyePoint, Inc.

Market Cap 34Cr 30Cr 28Cr 26Cr 48Cr 3.3TCr 48Cr 339.27Cr 130.92Cr 1.68TCr 129.22Cr 126.35Cr 5.4TCr P/E 2026 *
-1.09x
P/E 2027 * -1.53x
Enterprise Value 2.12Cr 1.85Cr 1.75Cr 1.58Cr 2.97Cr 203.37Cr 2.98Cr 21Cr 8.07Cr 103.39Cr 7.96Cr 7.78Cr 332.68Cr EV / Sales 2026 *
12.3x
EV / Sales 2027 * 1.65x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week-4.96%
Current month-10.67%
1 month-26.51%
3 months-70.40%
6 months-70.53%
Current year-78.00%
1 week 3.42
Extreme 3.415
4.34
1 month 3.42
Extreme 3.415
6.34
Current year 3.42
Extreme 3.415
18.87
1 year 3.42
Extreme 3.415
19.11
3 years 3.42
Extreme 3.415
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-1,39,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-4.96%-70.78%-58.39% 34Cr
-0.46%+2.62%+50.06%+100.41% 1,02700Cr
+0.29%+1.75%+55.16%+66.33% 65TCr
+0.24%+2.77%+19.03%+71.65% 47TCr
-1.22%+3.66%+36.44%+38.32% 35TCr
-0.79%+2.73%+19.03%+25.08% 27TCr
+0.58%+6.76%+11.13%+16.52% 26TCr
+0.90%+1.58%+38.97%+45.67% 21TCr
+0.79%+1.84%-28.27%-56.71% 19TCr
+0.01%+4.94%+32.74%+99.44% 19TCr
Average +0.05%+1.63%+16.35%+34.83% 36.02TCr
Weighted average by Cap. -0.12%+2.62%+34.89%+61.44%

Financials

2026 *2027 *
Net sales 17.18L 14.98L 14.15L 12.85L 24.07L 16Cr 24.17L 1.69Cr 65.4L 8.38Cr 64.55L 63.11L 27Cr 1.79Cr 1.56Cr 1.48Cr 1.34Cr 2.51Cr 172.01Cr 2.52Cr 18Cr 6.82Cr 87Cr 6.73Cr 6.58Cr 281.38Cr
Net income -34Cr -30Cr -28Cr -26Cr -48Cr -3.3TCr -48Cr -339.4Cr -130.97Cr -1.68TCr -129.27Cr -126.4Cr -5.4TCr -29Cr -25Cr -24Cr -21Cr -40Cr -2.75TCr -40Cr -282.61Cr -109.06Cr -1.4TCr -107.64Cr -105.25Cr -4.5TCr
Net Debt -32Cr -28Cr -27Cr -24Cr -45Cr -3.1TCr -45Cr -318.36Cr -122.85Cr -1.57TCr -121.26Cr -118.56Cr -5.07TCr -31Cr -27Cr -26Cr -24Cr -44Cr -3.02TCr -44Cr -310.14Cr -119.68Cr -1.53TCr -118.12Cr -115.5Cr -4.94TCr
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
18/26/18 $4.020 +0.75% 26,39,334
17/26/17 $3.990 +15.65% 69,75,498
16/26/16 $3.450 -5.74% 49,65,305
15/26/15 $3.660 -13.88% 38,94,199
14/26/14 $4.250 +0.47% 25,31,741
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
3.990USD
Average target price
25.91USD
Spread / Average Target
+549.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!